270 patents currently held
1 more in force is now held by another company
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
1 more record may belong here and awaits a decision; it is not counted.
The next term ends in Dec 2026. from the record
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
114
Ending by 2030
Dec 2026
Next term end
109
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 21, 2026 · includes USPTO assignment data published Nov 20, 2026, status data published Nov 21, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends Jan 2028 · High confidence
Also notable
Ends Nov 2027 · Medium confidence
Also notable
Ends Dec 2030 · High confidence
Also notable
Ends Sep 2030 · High confidence
Also notable
Ends Aug 2036 · High confidence
Also notable
Ends Dec 2029 · High confidence
Also notable
Ends Mar 2030 · High confidence
Also notable
Ends Nov 2030 · High confidence
Methods for Detecting Vitamin D Metabolites
US 7,745,226
The most cited patent in this portfolio, cited by 110 later US patents, top 10% of utility patents granted in 2010 in our data. Protection runs to 2028.
Methods for Detecting Dihydroxyvitamin D Metabolites by Mass Spectrometry
US 11,650,216
Cited by 8 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2027.
Mass Spectrometry of Steroidal Compounds in Multiplexed Patient Samples
US 10,955,424
Cited by 13 later US patents, top 25% of utility patents granted in 2021 in our data. Protection runs to 2030. A terminal disclaimer caps this term to an earlier patent's.
System and Method for Classification of Patients
US 8,999,648
Cited by 72 later US patents, top 10% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2030.
Quantitation of Insulin by Tandem Mass Spectrometry of Insulin B Chain
US 10,436,803
Cited by 33 later US patents, top 10% of utility patents granted in 2019 in our data. Protection runs to 2036.
Vitamin D Metabolite Determination Utilizing Mass Spectrometry Following Derivatization
US 7,977,117
Cited by 43 later US patents, top 25% of utility patents granted in 2011 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2029.
Mass Spectrometry Assay for Congenital Adrenal Hyperplasia
US 8,153,962
Cited by 29 later US patents, top 25% of utility patents granted in 2012 in our data, and renewed at 3 of 3 maintenance windows. Protection runs to 2030.
Methods for the Diagnosis of Bacterial Vaginosis
US 9,200,331
Cited by 19 later US patents, top 25% of utility patents granted in 2015 in our data, and renewed at every maintenance window due so far. Protection runs to 2030.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 8 fees due Dec 11 to 27, 2026 · next Dec 11
- 2 fees due Feb 8 to 20, 2027 · next Feb 8
- 4 fees due Mar 10 to 26, 2027 · next Mar 10
- 3 fees due Apr 1 to 17, 2027 · next Apr 1
- 6 fees due May 3 to 26, 2027 · next May 3
- 8 fees due Jun 1 to 30, 2027 · next Jun 1
- 4 fees due Jul 2 to 30, 2027 · next Jul 2
- 3 fees due Aug 9 to 27, 2027 · next Aug 9
- 1 fee due Sep 12, 2027The maintenance fee for Apolipoprotein E Isotype Detection by Mass Spectrometry (US 11,929,243) comes due Sep 12, 2027. Unpaid by Mar 13, 2028, it lapses early.
- 6 fees due Oct 9 to 23, 2027 · next Oct 9
- 2 fees due Nov 12 to 14, 2027 · next Nov 12
Recent changes
- 2 of the patents on this record were granted since Aug 23, 2026
What they patent
The largest of its 109 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,447,826 | Cystic Fibrosis Transmembrane Conductance Regulator Gene Mutations In force · Low confidence | In force | Low confidence | |
| US 8,013,186 | Haloalkyl Containing Compounds as Cysteine Protease Inhibitors In force · High confidence | In force | High confidence | |
| US 7,737,300 | Processes and Intermediates Preparing Cysteine Protease Inhibitors In force · High confidence | In force | High confidence | |
| US 8,092,996 | Method for Detecting Cystic Fibrosis In force · High confidence | In force | High confidence | |
| US 7,488,848 | Alpha Ketoamide Compounds as Cysteine Protease Inhibitors In force · High confidence | In force | High confidence | |
| US 8,709,818 | Lipoprotein Analysis by Differential Charged-Particle Mobility In force · High confidence | In force | High confidence | |
| US 9,046,539 | Lipoprotein Analysis by Differential Charged-Particle Mobility In force · Medium confidence | In force | Medium confidence | |
| US 10,308,680 | Magnetic Separation of Lipoproteins Using Dextran Sulfate In force · Low confidence | In force | Low confidence | |
| US 11,680,949 | Lipoprotein Analysis by Differential Charged-Particle Mobility In force · High confidence | In force | High confidence | |
| US 12,055,554 | Lipoprotein Analysis by Differential Charged-Particle Mobility In force · Medium confidence | In force | Medium confidence |
Also on record, not counted in the 270: 1 patent in force now held by others · 26 patents ended · 81 applications pending · 47 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.